M&A / Deals Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors BioPharma DiveThe Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) BioPharma Dive The Shanghai-based biotech has a cell therapy that, if successful in testing, could become the first treatment of its kind for liver cancer. M&A / DealsOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: RFK Jr. rewrites ACIP rules; Gilead, Roche dig into protein degradersNext: Bayer wins MHRA approval for Kerendia in heart failure Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
